New York, USA-based rare neurological disease drug developer Neurogene has announced positive interim clinical data in the first four participants in the low-dose cohort of its ongoing Phase I/II open ...

Lundbeck’s Q3 2024 revenue rose 18% to $815 million, driven by strategic brands like Vyepti and Rexulti in the USA. Vyepti’s ...

Syndax Pharmaceuticals (Nasdaq: SNDX) has announced that its Phase II AUGMENT-101 trial of experimental drug revumenib ...

Sino-American oncology company BeiGene (Nasdaq: BGNE) has announced third-quarter 2024 financials, showing the total revenues ...

Intercept Pharmaceuticals, now wholly owned subsidiary of Italy’s Alfasigma, today revealed that the US Food and Drug ...

The US Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug (IND) application for ...

Danish life sciences investor Novo Holdings is continuing the spread of its cash pile, this time as co-leader of a $181.4 ...

San Francisco-based Trace Neuroscience has launched with $101 million in series A funding to develop ALS therapies focused on ...

Norwegian clinical-stage biotech Nykode Therapeutics revealed that it has received notification from Genentech, a US ...

Novel MEK blocker shows promise in rare genetic disorder ...

German life sciences company Merck KGaA (MRK: DE) today announced that the Phase III MANEUVER trial of pimicotinib met its ...

While not everything appears rosy in one of AstraZeneca’s (LSE: AZN) major markets, the company has announced a huge ...